The prostate health index (PHI) density: Are there advantages over PHI or over the prostate-specific antigen density?

Overdiagnosis of prostate cancer (PCa) should be minimized. We wanted to evaluate the diagnostic performance health index density (PHID) and compare it with that (PHI) alone prostate-specific antigen (PSAD). 232 men scheduled for a biopsy (prostate-specific level: 2–10 µg/L), were enrolled. PHI, PHID PSAD evaluated considering PCa clinically significant (csPCa) as outcomes. For PCa, area under curve (AUC) was higher (0.823) than PHI (0.779) (0.776). csPCa, AUC also (0.851) but closer (0.819) (0.813). equal sensitivities (90%) offered highest specificities (37%), missing same number cancers (n = 11). Considering had similar specificities. reached specificity (50.0%), sparing 32.8% biopsies, while 9 cases csPCa. has better overall detection, very close performance. perform almost equally,